Our Team

Management Team

David Platt
CEO & Chairman
PhD
Dr. Platt is a world-renowned expert in carbohydrate chemistry who has founded three publicly traded companies, creating nearly $1B for investors. He has raised $150M directly in public markets in the U.S., and has led development of two drug candidates from concept through phase II clinical trials. Prior to BioXyTran Inc. Dr. Platt founded Boston Therapeutics Inc. in 2010 (OTC: BTHE). Between 2001 and 2009, Dr. Platt became a founder of Pro-Pharmaceuticals, Inc. (OTC: PRWP and AMEX: PRW, now NASDAQ: GALT), and served as its chief executive officer and board chairman. In 1995 Dr. Platt founded International Gene Group (NASDAQ: IGGI, GLGS now LPJC); he continued to serve the firm through 2000.
Ola Soderquist
CFO
CPA, CMA, CM&AA
Mr. Soderquist has more than 30 years of senior international entrepreneurial management experience within technology companies. He has served in CFO and other managerial capacities in multiple industry sectors and companies, such as Industrivarden (OMX:INDU), Electrolux (OMX:ELUX), Ericsson (NASDAQ:ERIC), Swedish Match (OMX:SWMA) and SKF AB (OMX:SKF), and most recently in Belden (NYSE: BDC) and Traction (OMX:TRAC). Ola is a multi-lingual senior finance professional poised to work globally and cross-functionally, particularly with complex projects involving business integration, systems implementation, continuous improvement, and process excellence. Ola’s managerial experience portfolio includes; Start-ups, Private, Public, Venture Capital and Private Equity ownership. He obtained a BS and an MS in Accounting from Stockholm School of Economics and an MBA from Babson College – Franklin W. Olin Graduate School of Business.
Elena Chekhova
Chief Scientist
PhD
Elena Chekhova received her Ph.D in Process Systems Engineering at MIT; Elena has over 10 years of experience in the life sciences industry Most recently she founded Biotine Consulting, a life science consultancy providing business development and project management services to life science companies in the US and internationally. Prior to founding Biotine, Elena served as Vice President of Business development at Chiral Quest, a manufacturing and technology start-up with offices in NJ and China.

Board of Directors

Anders N. Utter
Director
Financial Expert
Mr. Utter has more than 25 years of finance, accounting and management experience in medical devices, consulting and manufacturing industries in capacities as CFO, Controller and Managing Director. He had progressively increased management experience in the European Nolato Group and later on in the Amplex Group. Mr. Utter has had a broad business exposure with IFRS and GAAP reporting as well as with SOX compliance. He has also worked with M&A evaluations, financing and integration as well as more hands-on manufacturing cost accounting and reporting. He is currently in charge of the finance control at one of General Cable’s entities. Mr. Utter is and has been serving as a director on boards in both profit as well as non-profit organizations. Mr. Utter holds an MBA from Babson College and a BA from Uppsala University in Sweden.
Alan M. Hoberman
Director
PhD
Alan M. Hoberman, PhD is president and CEO of Argus International, Inc., overseeing a staff of scientists and other professionals who provide consulting services for industry, government agencies, law firms, and other organizations, both in the U.S. and internationally. Between 1991 and 2013 he held a series of positions of increasing responsibility at Charles River Laboratories Preclinical Services (formerly Argus Research Laboratories, Inc.), most recently as Executive Director of Site Operations and Toxicology. He currently works with that organization to design, supervise, and evaluate reproductive and developmental toxicity, neurotoxicity, inhalation, and photobiology studies. Dr. Hoberman holds a PhD in toxicology from Pacific Western University, an MS in interdisciplinary toxicology from the University of Arkansas, and a BS in biology from Drexel University.
Henry J. Esber
Director
PhD
Mr. Esber has been a principal in Esber D&D consulting since 2005. From 2003 to 2005, Dr. Esber was a Senior Consultant, Business Development at Charles River Labs, Discovery and Development Services. From 2005 to 2006, Dr. Esber was a consultant and from 2006, he was Senior Vice President and Chief Business Officer for Bio-Quant, which he had co-founded. Dr. Esber was also the co-founder of BioSignature Diagnostics, Inc. and Advanced Drug Delivery, Inc. From December 2009 to January 2013, Dr. Esber was a director of Apricus Biosciences, Inc., a public company with shares traded on the NASDAQ Capital Market. From April 2006 to February 2009, Dr. Esber was a director of Pro-Pharmaceuticals, Inc., a public company with shares traded on the NYSE Alternext US. He serves on the scientific advisory boards of several biotechnology companies and is the author of more than 130 technical publications. Dr. Esber has more than 35 years of experience in the areas of oncology/tumor immunology and immunotherapy as well as strong knowledge in the field of toxicology and regulatory affairs. Dr. Esber received a BS degree in biology/pre-med from the College of William and Mary, an MS degree in public health and parasitology from the University of North Carolina, and a PhD in immunology/microbiology from West Virginia University Medical Center. Dr. Esber was previously a director of the company from September 2009 through December 2010.
Dale H. Conaway
Director
DVM
Mr. Conaway is the Veterinary Medical Officer for the Office of Research Oversight, an office within the Veterans Health Administration under the US Department of Veterans Affairs. From 2001 to 2006, Dr. Conaway was the Deputy Regional Director (Southern Region). From 1998 to 2001, Dr. Conaway served as Manager of the Equine Drug Testing and Animal Disease Surveillance Laboratories for the Michigan Department of Agriculture. From 1994 to 1998, he was Regulatory Affairs Manager for the Michigan Department of Public Health Vaccine Production Division. From May 2001 to February 2009, Dr. Conaway was a director of Pro-Pharmaceuticals, Inc., a public company with shares traded on the NYSE Alternext US. Dr. Conaway received a DVM degree from Tuskegee Institute and an MS degree in pathology from the College of veterinary medicine at Michigan State University.
David Platt
CEO & Chairman of the Board
PhD
Dr. Platt is a world-renowned expert in carbohydrate chemistry who has founded three publicly traded companies, creating nearly $1B for investors. He has raised $150M directly in public markets in the U.S., and has led development of two drug candidates from concept through phase II clinical trials. Prior to BioXyTran Inc. Dr. Platt founded Boston Therapeutics Inc. in 2010 (OTC: BTHE). Between 2001 and 2009, Dr. Platt became a founder of Pro-Pharmaceuticals, Inc. (OTC: PRWP and AMEX: PRW, now NASDAQ: GALT), and served as its chief executive officer and board chairman. In 1995 Dr. Platt founded International Gene Group (NASDAQ: IGGI, GLGS now LPJC); he continued to serve the firm through 2000.

Advisory Board

Dr. Patrick Huddie
Advisory Board
PHD
Dr. Patrick Huddie, a partner of Westbury Group, is an experienced investment banker with substantial experience in advising entrepreneurial ventures in the healthcare sector. In the course of his career, he has advised many companies regarding mergers and acquisitions, as well as debt and equity financings. His clients have been primarily in the healthcare sector, including biotechnology, consumer goods, diagnostics, and medical devices. Previously Huddie founded and operated an electro-optical engineering services company that provided imaging and laser technology to federal government clients, as well as to biomedical research organizations and to the microelectronics industry. The company successfully licensed and implemented NASA technology to create compact ultraviolet lasers for terrestrial applications.
John Jensen
Advisory Board
John Jensen is a Managing Director of Westbury Group, an investment bank that focuses on broad advisory and execution services for middle-market companies. With more than forty years of investment banking experience, Jensen spent thirty-two years at Merrill Lynch, retiring as the Vice Chairman of Global Equity Capital Markets. In his career, he led the fundraising of more than $100 billion in equity offerings, including large, complex, global privatizations, such as France Telecom. After retiring from Merrill Lynch, Jensen founded a healthcare technology company, which was sold to a publicly held Belgian company in 2012. Jensen graduated from the University of North Carolina at Chapel Hill with a B.A. with Honors and he attended the New York University, Stern School of Business.
Cynthia Ekberg Tsai
ADVISORY BOARD
Ms. Tsai comes to Bioxytran with more than 30 years of experience in global biotechnology and medical technologies. Ms. Tsai spent 16 years on Wall Street as a Vice President with Merrill Lynch and Kidder Peabody. She currently is CEO of Tana Systems, a global software and IT company based in the U.S. and India. Ms. Tsai is the former Founder and CEO of HealthExpo, the largest consumer healthcare event in the US, where she grew the enterprise from concept to execution, attracting more than 50 million consumers to HealthExpo. Previously, Ms. Tsai was a General Partner in MassTech Ventures, a multi-million-dollar equity fund focused on technology development at Massachusetts Institute of Technology. Ms. Tsai currently serves on the Board of Selectors for the Jefferson Foundation Awards and is on the board of the Prix Galien Foundation. In 1999, the Harvard Business School Alumni Chapter in New York recognized Ms. Tsai with an Early Stage Honor Roll Award for Entrepreneurship. In 2004, she also received a “Leading Woman Entrepreneur of the World” Award from the Star Foundation in Overland Park, Kansas. She earned a B.A. in Psychology from the University of Missouri.
Jonathan Barkman
ADVISORY BOARD
Mr. Barkman has over 25 years of experience in the finance industry. This experience started with his initial days as a financial analyst and trader which lead to his leadership role as First Vice President of Janney Montgomery Scott. LLC and as Founder and CEO of Riverview Capital Enterprises LLC. Mr. Barkman became a trusted advisor to not only his individual clients but many small and micro-cap companies such as Bioxytran.
Steve Aust
ADVISORY BOARD
Steve Aust played Division 1 collegiate basketball for Pepperdine University and brings a passion for sports, competition, and leadership to all of his business pursuits. He has owned and operated direct sales and marketing companies in the nutritional, cosmetic, travel and entertainment businesses, was ranked as a top 100 Networkers for 12 years, built networks international distributors and is a former investment banker. Steve has firsthand experience of a loved one suffering through a stroke. He understood our value proposition immediately – buying stroke victims critical extra hours so that they can be treated before irreversible brain damage occurs. Mr. Aust is currently President of VRDT Corporation; and will provide strategic planning to building awareness of Bioxytran’s technology with key opinion leaders.
Dr. Juan Carlos Lopez-Telavera
Medical Advisory Board
PHD
Dr. Lopez-Talavera has over 20 years of experience in the biopharma industry, with extensive expertise in liver and gastrointestinal diseases. Most recently, Dr. Lopez-Talavera was Senior Vice President, Head of Medical Affairs and member of the Executive Team at Intercept Pharmaceuticals. Previously he held positions at AbbVie as Head of Medical Affairs, Global Research and Development, Bristol Myers Squibb, as Vice President and Global Development Lead, and Roche Laboratories as Senior Medical Director. Before moving into the industry, Dr. Lopez-Talavera was an Assistant Professor with the Divisions of Gastroenterology and Hepatology, and Endocrinology and Pathology at the University of Pittsburgh Medical Center, Associate Professor of Medicine with the Universidad Autónoma de Barcelona and Attending Physician of the Liver Unit at the Hospital General Universitari Vall D’Hebron in Barcelona.
Hana Chen-Walden
Medical Advisory Board
MD
Dr. Chen-Walden has specialized in regulatory affairs in the pharmaceutical industry in the US and Europe. She has thirty years of regulatory experience in EMEA and in individual European countries. Since 2004, She has consulted for the European Clinical and Regulatory Consultancy in medical monitoring, quality assurance, and regulatory input for clinical studies in the fields of oncology, cardiology, diabetes, neurology, respiratory diseases, and medical devices. From 2000 to 2003, Dr. Chen-Walden was Director of International Regulatory Affairs, Covalent Group Ltd. From 1997 to 2000, she was Medical, Drug Safety, and Regulatory Director at CRC, a clinical contract research organization in France. Dr. Chen-Walden received her MD degree from the University of Tel Aviv, Israel. She has practiced medicine in Germany and France.
Prof. Avraham Mayevsky
Scientific Advisory Board
PhD
Prof. Avraham Mayevsky is a worldwide authority in the field of minimal invasive monitoring of tissue and organ physiology. Prof. Mayevsky is a professor at the Faculty of Life Sciences, Bar-Ilan University, Israel. He founded Vital Medical Ltd. He served as Head of the Department of Life Sciences and Dean of the Faculty of Natural Sciences at Bar-Ilan University, where he established a center of tissue physiology. He served as Visiting professor at University of Pennsylvania and Johns Hopkins Medical School World-recognized expert in tissue physiology, especially in brain metabolism. He Published over 150 papers and patents. He has published over 170 papers in scientific journals and is the author of five patents. Prof. Mayevsky completed PhD from Weizmann Institute of Science, Rehovot, Israel.